Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 6 of 6
Full-Text Articles in Medicine and Health Sciences
Overall Survival And Histology-Specific Subgroup Analyses From A Phase 3, Randomized Controlled Study Of Trabectedin Or Dacarbazine In Patients With Advanced Liposarcoma Or Leiomyosarcoma, S. Patel, M. Von Mehren, D. R. Reed, P. Kaiser, J. Charlson, C. W. Ryan, D. Rushing, M. Livingston, R. G. Maki, G. D. Demetri, +10 Additional Authors
Overall Survival And Histology-Specific Subgroup Analyses From A Phase 3, Randomized Controlled Study Of Trabectedin Or Dacarbazine In Patients With Advanced Liposarcoma Or Leiomyosarcoma, S. Patel, M. Von Mehren, D. R. Reed, P. Kaiser, J. Charlson, C. W. Ryan, D. Rushing, M. Livingston, R. G. Maki, G. D. Demetri, +10 Additional Authors
Journal Articles
No abstract provided.
An Irak1-Pin1 Signalling Axis Drives Intrinsic Tumour Resistance To Radiation Therapy, P. H. Liu, R. B. Shah, Y. Li, A. Arora, P. M. Ung, R. Raman, A. Gorbatenko, S. Kozono, R. G. Maki, S. Sidi, +13 Additional Authors
An Irak1-Pin1 Signalling Axis Drives Intrinsic Tumour Resistance To Radiation Therapy, P. H. Liu, R. B. Shah, Y. Li, A. Arora, P. M. Ung, R. Raman, A. Gorbatenko, S. Kozono, R. G. Maki, S. Sidi, +13 Additional Authors
Journal Articles
No abstract provided.
Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms And Less Complete Recovery At One Year Compared To Unrelated Donors, M. A. Pulsipher, B. R. Logan, D. M. Kiefer, P. Chitphakdithai, M. L. Riches, D. Rizzo, P. Anderlini, R. Bayer, I. Sahdev, B. E. Shaw, +51 Additional Authors
Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms And Less Complete Recovery At One Year Compared To Unrelated Donors, M. A. Pulsipher, B. R. Logan, D. M. Kiefer, P. Chitphakdithai, M. L. Riches, D. Rizzo, P. Anderlini, R. Bayer, I. Sahdev, B. E. Shaw, +51 Additional Authors
Journal Articles
No abstract provided.
Probabilistic Modeling Of Personalized Drug Combinations From Integrated Chemical Screen And Molecular Data In Sarcoma, N. E. Berlow, R. Rikhi, M. Geltzeiler, J. Abraham, M. N. Svalina, L. E. Davis, E. Wise, M. Mancini, R. G. Maki, C. Keller, +19 Additional Authors
Probabilistic Modeling Of Personalized Drug Combinations From Integrated Chemical Screen And Molecular Data In Sarcoma, N. E. Berlow, R. Rikhi, M. Geltzeiler, J. Abraham, M. N. Svalina, L. E. Davis, E. Wise, M. Mancini, R. G. Maki, C. Keller, +19 Additional Authors
Journal Articles
No abstract provided.
A Phase 1 And Randomized Controlled Phase 2 Trial Of The Safety And Efficacy Of The Combination Of Gemcitabine And Docetaxel With Ontuxizumab (Morab-004) In Metastatic Soft-Tissue Sarcomas, R. L. Jones, S. P. Chawla, S. Attia, P. Schoffski, H. Gelderblom, B. Chmielowski, A. Le Cesne, B. A. Van Tine, J. C. Trent, R. G. Maki, +7 Additional Authors
A Phase 1 And Randomized Controlled Phase 2 Trial Of The Safety And Efficacy Of The Combination Of Gemcitabine And Docetaxel With Ontuxizumab (Morab-004) In Metastatic Soft-Tissue Sarcomas, R. L. Jones, S. P. Chawla, S. Attia, P. Schoffski, H. Gelderblom, B. Chmielowski, A. Le Cesne, B. A. Van Tine, J. C. Trent, R. G. Maki, +7 Additional Authors
Journal Articles
No abstract provided.
Eribulin Versus Dacarbazine In Patients With Leiomyosarcoma: Subgroup Analysis From A Phase 3, Open-Label, Randomised Study, J. Blay, P. Schoffski, S. Bauer, A. Krarup-Hansen, C. Benson, D. R. D'Adamo, Y. Jia, R. G. Maki
Eribulin Versus Dacarbazine In Patients With Leiomyosarcoma: Subgroup Analysis From A Phase 3, Open-Label, Randomised Study, J. Blay, P. Schoffski, S. Bauer, A. Krarup-Hansen, C. Benson, D. R. D'Adamo, Y. Jia, R. G. Maki
Journal Articles
No abstract provided.